Masoudi-Sobhanzadeh Yosef, Esmaeili Hosein, Masoudi-Nejad Ali
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Bioimpacts. 2022;12(4):315-324. doi: 10.34172/bi.2021.40. Epub 2021 Aug 10.
COVID-19 has spread out all around the world and seriously interrupted human activities. Being a newfound disease, not only many aspects of the disease are unknown, but also there is not an effective medication to cure the disease. Besides, designing a drug is a time-consuming process and needs large investment. Hence, drug repurposing techniques, employed to discover the hidden benefits of the existing drugs, maybe a useful option for treating COVID-19. The present study exploits the drug repositioning concepts and introduces some candidate drugs which may be effective in controlling COVID-19. The suggested method consists of three main steps. First, the required data such as the amino acid sequences of targets and drug-target interactions are extracted from the public databases. Second, the similarity score between the targets (protein/enzymes) and genome of SARS-COV-2 is computed using the proposed fuzzy logic-based method. Since the classical approaches yield outcomes which may not be useful for the real-world applications, the fuzzy technique can address the issue. Third, after ranking targets based on the obtained scores, the usefulness of drugs affecting them is examined for managing COVID-19. The results indicate that antiviral medicines, designed for curing hepatitis C, may also cure COVID-19. According to the findings, ribavirin, simeprevir, danoprevir, and XTL-6865 may be helpful in controlling the disease. It can be concluded that the similarity-based drug repurposing techniques may be the most suitable option for managing emerging diseases such as COVID-19 and can be applied to a wide range of data. Also, fuzzy logic-based scoring methods can produce outcomes which are more consistent with the real-world biological applications than others.
新冠病毒已在全球范围内传播,严重扰乱了人类活动。作为一种新发现的疾病,不仅该疾病的许多方面尚不清楚,而且还没有有效的药物来治愈它。此外,设计一种药物是一个耗时的过程,需要大量投资。因此,用于发现现有药物潜在益处的药物重新利用技术,可能是治疗新冠病毒的一个有用选择。本研究运用了药物重新定位的概念,并介绍了一些可能对控制新冠病毒有效的候选药物。所建议的方法包括三个主要步骤。首先,从公共数据库中提取所需数据,如靶点的氨基酸序列和药物 - 靶点相互作用数据。其次,使用所提出的基于模糊逻辑的方法计算靶点(蛋白质/酶)与新冠病毒基因组之间的相似性得分。由于传统方法产生的结果可能对实际应用没有用处,模糊技术可以解决这个问题。第三,根据获得的分数对靶点进行排名后,研究影响这些靶点的药物对管理新冠病毒的有效性。结果表明,用于治疗丙型肝炎的抗病毒药物也可能治愈新冠病毒。根据研究结果,利巴韦林、西米普韦、达诺普韦和XTL - 6865可能有助于控制该疾病。可以得出结论,基于相似性的药物重新利用技术可能是管理新冠病毒等新兴疾病的最合适选择,并且可以应用于广泛的数据。此外,基于模糊逻辑的评分方法可以产生比其他方法更符合实际生物应用的结果。